T3/T4 studies. Doesn't patient preference count as evidence?

[Guest guest]

In this summary of T3/T4 studies , Here, out of the 9 studies showed in the summary, 4 did not look for patient preference. Of the 5 that did, 3 shows a preference to T3 + T4, one found the preference to be equal for both treatments, and one found preference to be for the T4 only. The latter thought is now known to have use a proportion of T3 that is far too high. – "We know nowadays that all their patients were overtreated, with the adverse effects using the combinations being easily explained by the addition of 40–60 µg liothyronine to an already excessive levothyroxine dose" (from Escobar-Morreale et al). So it is no wonder most preferred T4 only.The Escobar-Morreale et al study (Here)shows that there were (seemingly) no advantages to T3 + T4 therapy, and that there was a disadvantage (increased urinary concentrations of bone remodelling markers)Despite this 12/26 patients preferred T3+T4 therapy in the proportion 15:1, 6 preffered T3 + T4 in the proportion 11.7:1, 2 preferred the T4 only and 6 had no preference.About ¾ of patients preferred the T3 + T4 therapy. Doesn't this show that the tests used to monitor the performance of either medication (ie. Quality of life, mood etc.) do not tell the whole story? There was seemingly no benefit using these tests, so why did ¾ of patients prefer the combined treatment?I don't think it is coincidence either as "This preference for the combined therapy might have resulted from chance. But patients in the Bunevicius et al. (30) study also preferred levothyroxine plus liothyronine combinations, and a similar result has been recently confirmed in a large study conducted in The Netherlands by Appelhof et al. (45)." (from Escobar-Morreale et al)In the Bunevicius et al. Study 20 patients preferred thyroxine plus triiodothyronine, 11 had no preference, and 2 preferred thyroxine alone. This is almost a 2/3 preference to T3+T4. I couldnt find the Appelhof et al. study.Out of the 9 studies showed in the summary, 4 did not look for patient preference. Of the 5 that did, 3 shows a preference to T3 + T4, one found the preference to be equal for both treatments, and one found preference to be for the T4 only. The latter thought is now known to have use a proportion of T3 that is far too high. – "We know nowadays that all their patients were overtreated, with the adverse effects using the combinations being easily explained by the addition of 40–60 µg liothyronine to an already excessive levothyroxine dose" (from Escobar-Morreale et al). So it is no wonder most preferred T4 only.Overall, even though there is not hard proof of the benefit of T3 + T4 therapy, dowsn't the patients preference count for anything? In my mind it makes me think that the combined treatment is having an effect that is not, or cannot be, measured in any way.Also: these studies use T3 and T4, but not Armour, so patients are still not getting all the hormones (T1, T2 ..) that they naturally would. Dos anyone know if there are any studies that have used Armour? If not, would one that did be interesting?Jonny